Journal articles: 'CVP analysis'

1

Derighetti, Antoine. "Conditional expectations on CVp(G). Applications." Journal of Functional Analysis 247, no. 1 (June 2007): 231–51. http://dx.doi.org/10.1016/j.jfa.2007.03.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jakupi, Shefket Zeqir, Bedri Statovci, and Besart Hajrizi. "Break-Even Analysis as a powerful tool in Decision-Making." International Journal of Management Excellence 9, no. 3 (October 31, 2017): 1169–71. http://dx.doi.org/10.17722/ijme.v9i3.940.

Full text

Abstract:

This research paper is based on the contemporary techniques presented in the discipline of CVP Analysis. Techniques applied to carry out a complete and accurate financial analysis based on the CVP Analysis. In this paper, an application of theoretical concepts of the CVP Analysis has been realized. The quality of information and the recognition of specific features of business activity influence the achievement of a qualitative analysis. The cost-volume-profit analysis (CVP Analysis) is a powerful tool for planning and making decisions. Since the CVP analysis highlights the reciprocal cost ratio, the quantity sold and the price, it brings together all the financial information of the enterprise.

APA, Harvard, Vancouver, ISO, and other styles

3

Sanfilippo, Filippo, Alberto Noto, Gennaro Martucci, Marco Farbo, Gaetano Burgio, and Daniele G. Biasucci. "Central venous pressure monitoring via peripherally or centrally inserted central catheters: a systematic review and meta-analysis." Journal of Vascular Access 18, no. 4 (June 23, 2017): 273–78. http://dx.doi.org/10.5301/jva.5000749.

Full text

Abstract:

Introduction The central venous pressure (CVP) is the most commonly used static marker of preload for guiding fluid therapy in critically ill patients, though its usefulness remains controversial. Centrally inserted central catheters (CICCs) are the gold-standard devices for CVP monitoring but peripherally inserted central catheters (PICCs) may represent a valid alternative. We undertook a systematic review and meta-analysis with the aim to investigate whether the difference between PICC- and CICC-measured CVP is not significant. Methods We searched for clinical studies published in PubMed and EMBASE databases from inception until December 21st 2016. We included studies providing data on paired and simultaneous CVP measurement from PICCs and CICCs. We conducted two analyses on the values of CVP, the first one according to the total number of CVP assessments, the second one considering the number of patients recruited. Results Four studies matched the inclusion criteria, but only three of them provided data for the meta-analyses. Both analyses showed non-significant differences between PICC-measured and CICC-measured CVP: 1489 paired simultaneous CVP assessments (MD 0.16, 95%CI −0.14, 0.45, p = 0.30) on a total of 57 patients (MD 0.22, 95%CI −1.46, 1.91, p = 0.80). Both analyses showed no heterogeneity (I2 = 0%). Conclusions Available evidence supports that CVP monitoring with PICCs is accurate and reproduces similar values to those obtained from CICCs. The possibility to monitor CVP should not be used among clinical criteria for preferring a CICC over a PICC line.

APA, Harvard, Vancouver, ISO, and other styles

4

Dianawati, Wiwiek. "Cost-Volume-Profit Analysis Untuk Kondisi Uncertainty." AKRUAL: Jurnal Akuntansi 2, no. 1 (October 11, 2010): 43. http://dx.doi.org/10.26740/jaj.v2n1.p43-54.

Full text

Abstract:

AbstrackHotels tend to have a high level of fixed cost owing to the levels of investment required. This should result in above normal profits in good times, as variable costs remaining will form a smaller proportion of additional revenue. However, while high profits can be achieved above the break-even point, high losses will result if revenue is significantly reduced. Thus much attention is given to the traditional CVP model (which ignores uncertainty), as failure to cover fixed costs in the long term can result bankruptcy for organization. This article examines the basic CVP model and describes how to include uncertainty during the decision making process.Key words: CVP model, Break-Even Point, uncertainty

APA, Harvard, Vancouver, ISO, and other styles

5

Sala-Mercado, Javier A., Mohsen Moslehpour, Robert L. Hammond, Masashi Ichinose, Xiaoxiao Chen, Sell Evan, Donal S. O'Leary, and Ramakrishna Mukkamala. "Stimulation of the cardiopulmonary baroreflex enhances ventricular contractility in awake dogs: a mathematical analysis study." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 307, no. 4 (August 15, 2014): R455—R464. http://dx.doi.org/10.1152/ajpregu.00510.2013.

Full text

Abstract:

The cardiopulmonary baroreflex responds to an increase in central venous pressure (CVP) by decreasing total peripheral resistance and increasing heart rate (HR) in dogs. However, the direction of ventricular contractility change is not well understood. The aim was to elucidate the cardiopulmonary baroreflex control of ventricular contractility during normal physiological conditions via a mathematical analysis. Spontaneous beat-to-beat fluctuations in maximal ventricular elastance ( Emax), which is perhaps the best available index of ventricular contractility, CVP, arterial blood pressure (ABP), and HR were measured from awake dogs at rest before and after β-adrenergic receptor blockade. An autoregressive exogenous input model was employed to jointly identify the three causal transfer functions relating beat-to-beat fluctuations in CVP to Emax (CVP → Emax), which characterizes the cardiopulmonary baroreflex control of ventricular contractility, ABP to Emax, which characterizes the arterial baroreflex control of ventricular contractility, and HR to Emax, which characterizes the force-frequency relation. The CVP → Emax transfer function showed a static gain of 0.037 ± 0.010 ml−1 (different from zero; P < 0.05) and an overall time constant of 3.2 ± 1.2 s. Hence, Emax would increase and reach steady state in ∼16 s in response to a step increase in CVP, without any change to ABP or HR, due to the cardiopulmonary baroreflex. Following β-adrenergic receptor blockade, the CVP → Emax transfer function showed a static gain of 0.0007 ± 0.0113 ml−1 (different from control; P < 0.10). Hence, Emax would change little in steady state in response to a step increase in CVP. Stimulation of the cardiopulmonary baroreflex increases ventricular contractility through β-adrenergic receptor system mediation.

APA, Harvard, Vancouver, ISO, and other styles

6

González, Luis. "Multiproduct CVP analysis based on contribution rules." International Journal of Production Economics 73, no. 3 (October 2001): 273–84. http://dx.doi.org/10.1016/s0925-5273(01)00116-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Zaichko, N. V., D. O. Nekrut, M. B. Lutsyuk, and M. A. Artemchuk. "Analysis of some homocysteine contradictions." Reports of Vinnytsia National Medical University 22, no. 1 (August 8, 2018): 233–37. http://dx.doi.org/10.31393/reports-vnmedical-2018-22(1)-45.

Full text

Abstract:

The existence of contradictory data in the literature and the lack of convincing evidence of the causes of hyperhomocysteinemia syndrome (HHC) associated with the disease give opposing views to the practical significance of high levels of homocysteine (HC) in plasma in patients. The article is written for the aim of having theoretical analysis of ambiguous, sometimes paradoxical data, on the problem of HHC, on the example of its association with cardiovascular pathology (CVP). The following paradoxes are formulated. The first paradox: in the part of clinical work, there was no link between moderate HHC and the risk of CVP. The second paradox: the prescription of vitamin B6, B9, B12 to patients for the prevention and treatment of CVP is usually accompanied by a significant reduction in the level of HC in plasma, but is not always realized by a decrease in the number of cardiovascular events. The third paradox: the mechanisms of the occurrence of HHC have not yet been identified in people with CVP or other diseases that correlate with the level of HC. Exceptions are only cases of these people having insufficient vitamins B6, B9, B12 taking part in the exchange of HC, or congenital defects of enzymes metabolism HC. The fourth paradox: in contrast to controversial clinical research, the results of experimental work are virtually unequivocal - artificial HHC pathogenetically associated with the development of CVP and other types of associated pathology. Thus, analysis of literary sources suggests the existence of opposing opinions, especially clinicians, about the role of HHC in the formation of cardiovascular pathology and the benefits of hypohomocysteinemic therapy. We believe that a definite value for the explanation of the contradictions will be focused research in the following areas: a) whether an increased level of HC is a cause, marker or consequence of cardiovascular disease; and b) whether HC is only a passive intermediate catabolism product of methionine or a biologically active compound with specific metabolic functions, the violation of which may take place both in the HHC, as well as due to hypohomocysteinemic therapy.

APA, Harvard, Vancouver, ISO, and other styles

8

Solal-Celigny, Philippe, Kevin Imrie, Andrew Belch, Katherine Sue Robinson, David Cunningham, Antonio Rueda, John Catalano, et al. "Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up." Blood 106, no. 11 (November 16, 2005): 350. http://dx.doi.org/10.1182/blood.v106.11.350.350.

Full text

Abstract:

Abstract Design/Methods: We recently demonstrated in a phase III trial that the addition of rituximab to each of 8 cycles of CVP (R-CVP) chemotherapy significantly improves the clinical outcome of previously untreated patients with stage III/IV CD20 positive follicular NHL when compared to CVP alone (Marcus et al., Blood2005; 105: 1417–23). A multivariate Cox regression analysis of time to progression or death (TTP) showed a treatment benefit in all patient subgroups according to baseline risk factors, except for patients with a baseline hemoglobin level below normal. We now present an updated analysis of all major trial endpoints with 42 months follow-up (FU). Results: A total of 321 patients (median age 53 years) were recruited (159 CVP, 162 R-CVP). Approximately half of the patients had high-risk disease according to the Follicular Lymphoma International Prognostic Index (FLIPI, score 3–5). The median TTP was more than doubled for patients receiving R-CVP compared to CVP alone (33.6 months vs 14.5 months, p<0.0001). Median time to new lymphoma treatment or death (TNLT) was 12.3 months in the CVP group and nearly quadrupled to 46.3 months in the R-CVP group (p<0.0001). Superior response rates for R-CVP were confirmed (CR+CRu rate 41% vs 11%, p<0.0001) with a median response duration (DR) of 13.5 months in the CVP arm versus 37.7 months in the R-CVP arm. Median disease free survival (DFS) in complete responders was 44.8 months for patients receiving R-CVP and 20.5 months in patients receiving CVP alone (p=0.0005). Thirty-five patients in the CVP arm and 23 patients in the R-CVP arm have died. Kaplan-Meier estimates of 3-year OS rates were 81% in the CVP arm and 89% in the R-CVP (p=0.07). Importantly, significantly more patients receiving CVP died due to lymphoma progression compared to patients receiving R-CVP (25 vs 12 deaths, p=0.02). Subgroup analysis for TTP, ORR, DR and OS according to risk factors at baseline are ongoing and will be presented. Conclusion: With longer FU, the combination of 8 cycles of rituximab with CVP chemotherapy continues to provide a major benefit as first line treatment for patients with advanced stage follicular NHL. Kaplan Meier plot of time to death due to disease progression Kaplan Meier plot of time to death due to disease progression

APA, Harvard, Vancouver, ISO, and other styles

9

Alavi-Moghaddam, Mostafa, Ali Kabir, Majid Shojaee, Mohammad Manouchehrifar, and Mehrdad Moghimi. "Ultrasonography of inferior vena cava to determine central venous pressure: a meta-analysis and meta-regression." Acta Radiologica 58, no. 5 (September 30, 2016): 537–41. http://dx.doi.org/10.1177/0284185116663045.

Full text

Abstract:

Background Until now, no valid alternative exists for predicting central venous pressure (CVP) with lower invasiveness than central venous catheter. Purpose To explore inferior vena cava diameter (IVCD) measurement accuracy by ultrasonography as a surrogate variable for determination of central venous pressure (CVP). Material and Methods A systematic review and meta-analysis of all published studies in PubMed, Scopus, Web of Knowledge, and Google Scholar were conducted from inception to July 2013. We used the STROBE checklist for quality assessment and meta-regression. Results Thirty-seven papers with 2843 cases were identified. The correlation coefficients between each one of IVCD, inspiratory IVC (iIVC), IVC collapsibility index (IVCCI), and expiratory IVC (eIVC) with CVP, were 0.68, 0.60, 0.54, and 0.44, respectively. There was no evidence of publication bias ( P = 0.28). Based on meta-regression, male gender was an important source of heterogeneity (OR = 1.01; 95% confidence interval, 1–1.03), which resulted in a higher correlation between IVCD and CVP. The present study showed a higher strength of association with CVP pertaining to IVCD, iIVC, IVCCI, and eIVC, respectively, and they were higher in men. Conclusion This study does not support the measurement of IVCD by ultrasonography as an acceptable surrogate variable to determine CVP among critical patients.

APA, Harvard, Vancouver, ISO, and other styles

10

Ermekbaev, A. Z., and S. A. Kim. "CVP -ANALYSIS AS A TOOL FOR EFFECTIVE BUSINESS PLANNING." EurasianUnionScientists 1, no. 69 (2019): 18–21. http://dx.doi.org/10.31618/esu.2413-9335.2019.1.69.472.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Kim, Seung Hwan. "Cost-Volume-Profit Analysis for a Multi-Product Company: Micro Approach." International Journal of Accounting and Financial Reporting 1, no. 1 (January 14, 2015): 23. http://dx.doi.org/10.5296/ijafr.v5i1.6832.

Full text

Abstract:

Cost-volume-profit (CVP) analysis is one of the most common-and-important chapters in an introductory managerial accounting course. While a CVP analysis for a single-product company is relatively easier to be illustrated, the CVP analysis for a multi-product company necessarily takes extra steps to illustrate. For the case of a multi-product company having a sales mix ratio among their products, this study developed a micro approach to the handling of decimals, if appearing, when the company finds their break-even point and target profit point. This study exemplifies how the developed approach gets to closer answers to a break-even point and a target profit point than an existing approach.

APA, Harvard, Vancouver, ISO, and other styles

12

Marcus, Robert, Kevin Imrie, Philippe Solal-Celigny, John V. Catalano, Anna Dmoszynska, João C. Raposo, Fritz C. Offner, et al. "Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma." Journal of Clinical Oncology 26, no. 28 (October 1, 2008): 4579–86. http://dx.doi.org/10.1200/jco.2007.13.5376.

Full text

Abstract:

PurposeTo compare the long-term outcome of patients with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and prednisone (CVP) versus CVP plus rituximab (R-CVP) and to evaluate the predictive value of known prognostic factors after treatment with R-CVP.Patients and MethodsPatients with previously untreated CD20-positive stage III/IV FL were randomly assigned to eight cycles of R-CVP (n = 159) or CVP alone (n = 162). The median follow-up period was 53 months.ResultsThe primary end point—time to treatment failure (TTF), which included patients without a response after four cycles as an event—was significantly prolonged in patients receiving R-CVP versus CVP (P < .0001). Improvements in all other end points, including overall and complete response rates (P < .0001), time to progression (TTP; P < .0001), response duration (P < .0001), time to next antilymphoma treatment (P < .0001), and overall survival (OS; P = .029; 4-year OS: 83% v 77%;) were achieved with R-CVP versus CVP alone. Univariate analyses demonstrated an improvement in TTP with R-CVP versus CVP irrespective of the Follicular Lymphoma International Prognostic Index (FLIPI) subgroup, the International Prognostic Index (IPI) subgroup, baseline histology, and the presence or absence of B symptoms or bulky disease. By multivariate analysis, FLIPI retains a strong predictive power for TTP in the presence of the trial treatment effect.ConclusionAnalysis of all outcome measures, including OS, confirm the benefit of adding R to CVP in the front-line treatment of FL.

APA, Harvard, Vancouver, ISO, and other styles

13

House, Andrew A., Mikko Haapio, Paolo Lentini, Ilona Bobek, Massimo de Cal, Dinna N. Cruz, Grazia M. Virzì, et al. "Volume Assessment in Mechanically Ventilated Critical Care Patients Using Bioimpedance Vectorial Analysis, Brain Natriuretic Peptide, and Central Venous Pressure." International Journal of Nephrology 2011 (2011): 1–5. http://dx.doi.org/10.4061/2011/413760.

Full text

Abstract:

Purpose. Strategies for volume assessment of critically ill patients are limited, yet early goal-directed therapy improves outcomes. Central venous pressure (CVP), Bioimpedance Vectorial Analysis (BIVA), and brain natriuretic peptide (BNP) are potentially useful tools. We studied the utility of these measures, alone and in combination, to predict changing oxygenation.Methods. Thirty-four mechanically ventilated patients, 26 of whom had data beyond the first study day, were studied. Relationships were assessed between CVP, BIVA, BNP, and oxygenation index (O2I) in a cross-sectional (baseline) and longitudinal fashion using both univariate and multivariable modeling.Results. At baseline, CVP and O2I were positively correlated (R=0.39;P=.021), while CVP and BIVA were weakly correlated (R=-0.38;P=.025). The association between slopes of variables over time was negligible, with the exception of BNP, whose slope was correlated with O2I (R=0.40;P=.044). Comparing tertiles of CVP, BIVA, and BNP slopes with the slope of O2I revealed only modest agreement between BNP and O2I (kappa=0.25;P=.067). In a regression model, only BNP was significantly associated with O2I; however, this was strengthened by including CVP in the model.Conclusions. BNP seems to be a valuable noninvasive measure of volume status in critical care and should be assessed in a prospective manner.

APA, Harvard, Vancouver, ISO, and other styles

14

Babiak, N., and N. Krutous. "CVP-analysis in the conditions of multiproduct manufacturing as a tool of operational controlling." UKRAINIAN BLACK SEA REGION AGRARIAN SCIENCE 109, no. 1 (2021): 11–19. http://dx.doi.org/10.31521/2313-092x/2021-1(109)-2.

Full text

Abstract:

CVP-analysis in the conditions of multiproduct manufacturing as a tool of operational controlling The peculiarities of CVP analysis in conditions of multiproduct manufacturing are revealed, comparing methods of its implementation are carried out. The possibilities of application the results of analysis when making managerial decisions in the operating system are determined. The problem of distribution of general constant retained expenses on separate types of products by various methods, as well as the definition of a break-free level of production and realization of certain types of products based on weighted average margin profits, are investigated. The impact on the profit of changing the level of constant costs and specific variables of expenses through an operating lever within the production enterprise is investigated. Keywords: CVP analysis, variable costs, fixed costs, marginal profit, break-even point, operational analysis, operational controlingl.

APA, Harvard, Vancouver, ISO, and other styles

15

Du, Yu－Wei, and Sang－Kyu Park. "Earning Asymmetries and CVP Analysis for External Users." Korean Journal of Accounting Research 21, no. 5 (October 31, 2016): 95. http://dx.doi.org/10.21737/kjar.2016.10.21.5.95.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Blocher, Edward, and Kung H. Chen. "The ALLTEL Pavilion Case: Strategy and CVP Analysis." Issues in Accounting Education 19, no. 4 (November 1, 2004): 555–65. http://dx.doi.org/10.2308/iace.2004.19.4.555.

Full text

Abstract:

The ALLTEL Pavilion case is intended for the undergraduate management accounting or cost accounting course and the M.B.A. management accounting course. It provides an excellent context in which to examine strategic issues in using cost volume profit (CVP) in a service business. Based on an actual entertainment pavilion, the case develops many factors unique to a service business and illustrates how pavilion management can use CVP analysis to determine which artists to attract and what kinds of contracts to have with these performers. The Pavilion has two types of customers (paying ticket holders and free ticket holders) and earns profits from three types of revenues (ticket revenues, concession revenues, and parking fees). The case requires you to identify the best strategy for different types of artists, conduct cost-volume-profit analyses, consider the strategic issues related to operating leverage and how this affects the choice of performer and contract, and assess pricing strategies.

APA, Harvard, Vancouver, ISO, and other styles

17

Ali, Md Rostam, and Syed Moudud-Ul-Huq. "Textile Industry in Bangladesh : An Analysis of CVP." Management Studies and Economic Systems 2, no. 4 (March 2016): 287–98. http://dx.doi.org/10.12816/0035636.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Fu, Lianzhi. "Improvements in the analysis of Kannan's CVP algorithm." Theoretical Computer Science 621 (March 2016): 103–12. http://dx.doi.org/10.1016/j.tcs.2016.01.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Liang, Hongyan, Alfred L. Guiffrida, Zilong Liu, Butje Eddy Patuwo, and Murali Shanker. "A Generalized Stochastic Cost–Volume–Profit Model." Systems 9, no. 4 (November 11, 2021): 81. http://dx.doi.org/10.3390/systems9040081.

Full text

Abstract:

Cost–volume–profit (CVP) analysis is a widely used decision tool across many business disciplines. The current literature on stochastic applications of the CVP model is limited in that the model is studied under the restrictive forms of the Gaussian and Lognormal distributions. In this paper we introduce the Mellin Transform as a methodology to generalize stochastic modeling of the CVP problem. We demonstrate the versatility of using the Mellin transform to model the CVP problem, and present a generalization of the CVP model when the contribution margin and sales volume are both defined by continuous random distributions.

APA, Harvard, Vancouver, ISO, and other styles

20

DOGADAYLO, Ya, and A. LABOONSKAYA. "METHOD OF STATISTICAL ACCOUNTING ANALYSIS AS AN INSTRUMENT OF CVP-ANALYSIS." Economics of the transport complex, no. 32 (December 10, 2018): 152. http://dx.doi.org/10.30977/etk.2225-2304.2018.32.0.152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Prakash, Jay, Natesh S. Rao, Sanjeev Kumar, Kumar H. Raghwendra, Khushboo Saran, and Sandeep D. Reddy. "Study of Relationship between Central Venous Pressure and Peripheral Venous Pressure during Intraoperative Period in Neurosurgical Patients." Journal of Neuroanaesthesiology and Critical Care 05, no. 01 (January 2018): 15–20. http://dx.doi.org/10.1055/s-0037-1618328.

Full text

Abstract:

Abstract Background and Objectives Central venous pressure (CVP) and peripheral venous pressure (PVP) are strongly correlated during various surgeries. This study was designed to examine the consistency of CVP–PVP relationships in circumstances of rapidly fluctuating hemodynamics in neurosurgical patients. Prime objective of this study was to determine if PVP can be an effective alternative to invasive CVP for assessing volume status during neurosurgical procedures when expertise, equipment, and patient’s condition contraindicate invasive monitoring. Subjects and Methods After the approval by the Institutional Ethics Committee, CVP and PVP were measured in 50 neurosurgical patients of the American Society of Anesthesiologists grade I and II operated in supine position. Paired measurements of CVP and PVP were made every 20 minutes, from the starting of anesthesia until the end of surgery; however, in situations of hemodynamic instability, the readings were taken every 5 minutes of interval. Results The study showed a strong correlation between CVP and PVP (Pearson’s correlation coefficient between CVP and PVP, r = 0.89; 95% CI: 0.81–0.93; p < 0.001). Mean CVP was 5.7 ± 0.8 mm of Hg, mean PVP was 10.4 ± 0.6 mm of Hg, and bias between CVP and PVP was 4.7 ± 0.4 (95% CI: − 4.61 to − 4.83). The Bland–Altman analysis showed that limit of agreement to be 4.0 to 5.5 mm of Hg. Conclusion This study demonstrated a strong correlation between CVP and PVP. Therefore, PVP monitoring may be a reliable alternative to CVP monitoring during neurosurgery.

APA, Harvard, Vancouver, ISO, and other styles

22

Smith, Delaney, Michael Thonney, Katherine Petersson, and Maria L. Hoffman. "PSIV-11 Effects of feeding a 50% cranberry vine pellet on milk components during lactation in sheep." Journal of Animal Science 99, Supplement_3 (October 8, 2021): 300. http://dx.doi.org/10.1093/jas/skab235.551.

Full text

Abstract:

Abstract The objective of this study was to examine the effect of feeding cranberry vine (CV) on milk components during early lactation as part of a larger study on the antiparasitic efficacy of CV supplementation on ewes during the periparturient period. Ewes were fed a 50% CV pellet (CVP; n = 12) or a control pellet (CON; n = 13) beginning at 102±1 d of pregnancy until d 65±1 postpartum. The CV pellet fed was formulated to be equivalent in digestible dry matter to the control pellet. BW was determined weekly during the study and milk samples were collected weekly during lactation. Data were analyzed in SAS with repeated measures. Ewe BW were similar at the start of study (180.36lbs ± 4.70lbs; P = 0.43) however by wk 8 postpartum CVP ewes weighed less than CON ewes (CON: 212.31lbs±7.86lbs; CVP: 185.58lbs±8.00lbs; P = 0.04). There was a treatment*wk effect observed for milk fat, protein and MUN (P ≤ 0.05). Ewes fed CVP exhibited reduced milk fat at wks 2 (CON: 6.75%±0.63%; CVP: 6.06%±0.58%; P = 0.03) and 5 (CON: 6.66%±0.37%; CVP: 5.54%±0.26%; P = 0.05), milk protein was reduced in CVP ewes at wk 2 (CON: 4.92%±0.12%; CVP: 4.72%±0.19%; P = 0.05) and MUN was greater at weeks 4 (CON: 22.89±0.7mg/dL; CVP: 27.93±0.85mg/dL; P = 0.01) and 8 (CON: 24.80±0.51mg/dL; CVP: 26.64±0.86mg/dL; P < 0.01) in CVP ewes. Somatic cell analysis is pending. In conclusion, CVP supplementation during lactation affects milk composition in sheep. Studies are underway to determine the effect of CV supplementation on additional metabolic parameters in pregnant and lactating ewes.

APA, Harvard, Vancouver, ISO, and other styles

23

Ryan, Declan, Jorgen Wullems, Georgina Stebbings, Christopher Morse, Claire Stewart, and Gladys Onambele-Pearson. "Segregating the Distinct Effects of Sedentary Behavior and Physical Activity on Older Adults’ Cardiovascular Structure and Function: Part 1—Linear Regression Analysis Approach." Journal of Physical Activity and Health 15, no. 7 (July 1, 2018): 499–509. http://dx.doi.org/10.1123/jpah.2017-0325.

Full text

Abstract:

Background: Physical behavior [PB, physical activity (PA), and sedentary behavior (SB)] can adjust cardiovascular mortality risk in older adults. The aim of this study was to predict cardiovascular parameters (CVPs) using 21 parameters of PB. Methods: Participants [n = 93, 73.8 (6.23) y] wore a thigh-mounted accelerometer for 7 days. Phenotype of the carotid, brachial, and popliteal arteries was conducted using ultrasound. Results: Sedentary behavior was associated with one of the 19 CVPs. Standing and light-intensity PA was associated with 3 and 1 CVP, respectively. Our prediction model suggested that an hourly increase in light-intensity PA would be negatively associated with popliteal intima-media thickness [0.09 mm (95% confidence interval, 0.15 to 0.03)]. sMVPA [moderate–vigorous PA (MVPA), accumulated in bouts <10 min] was associated with 1 CVP. 10MVPA (MVPA accumulated in bouts ≥10 min) had no associations. W50% had associations with 3 CVP. SB%, alpha, true mean PA bout, daily sum of PA bout time, and total week 10MVPA each were associated with 2 CVP. Conclusions: Patterns of PB are more robust predictors of CVP than PB (hours per day). The prediction that popliteal intima-media thickness would be negatively associated with increased standing and light-intensity PA engagement suggests that older adults could obtain health benefits without MVPA engagement.

APA, Harvard, Vancouver, ISO, and other styles

24

Potts, J. T., X. Shi, and P. B. Raven. "Cardiopulmonary baroreceptors modulate carotid baroreflex control of heart rate during dynamic exercise in humans." American Journal of Physiology-Heart and Circulatory Physiology 268, no. 4 (April 1, 1995): H1567—H1576. http://dx.doi.org/10.1152/ajpheart.1995.268.4.h1567.

Full text

Abstract:

Numerous studies have reported that, at rest, maximal carotid baroreflex gain is modulated by cardiopulmonary baroreceptors. The purpose of this study was to measure the maximal gain for carotid baroreflex control of heart rate (HR) and blood pressure [mean arterial pressure (MAP)] during dynamic exercise alone and when exercise was accompanied by two levels of cardiopulmonary baroreceptor unloading. Lower body negative pressure (LBNP) produced similar reductions in central venous pressure (CVP) at rest and during exercise. Baroreflex gain for HR at rest was not affected by low-level LBNP but was significantly increased by high-level LBNP [-0.31 +/- 0.05 to -0.57 +/- 0.23 beats.min-1.mmHg-1 carotid sinus pressure (CSP), no LBNP vs. high-level LBNP, P < 0.05]. Exercise combined with low- and high-level LBNP resulted in reflex HR gains (-0.83 +/- 0.44 and -0.83 +/- 0.17 beats.min-1.mmHg-1 CSP, low- vs. high-level LBNP, P < 0.05) that were significantly greater than the algebraic sum of the HR gain measured during exercise and LBNP alone. Neither exercise nor the two levels of LBNP significantly altered baroreflex gain for MAP. The slope relating HR gain to CVP at rest was significant (0.07 +/- 0.02 beats.min-1.mmHg CSP-1.mmHg CVP-1, P < 0.01) and increased 114% during exercise (P < 0.05). A similar analysis of MAP gain found no difference in slope between rest and exercise (P > 0.05). Together these data indicate 1) a tonic inhibitory interaction between cardiopulmonary baroreceptors and carotid baroreflex control of HR during exercise, and 2) a nonlinear relationship between deactivation of cardiopulmonary baroreceptors and changes in carotid baroreflex gain. This interaction may improve overall cardiovascular regulation when central blood volume and/or CVP is reduced, as has been reported during prolonged exercise in the heat.

APA, Harvard, Vancouver, ISO, and other styles

25

MacDonald, David, Richard van der Jagt, John M. Burke, Brad S. Kahl, Peter Wood, Tim E. Hawkins, Mark Hertzberg, et al. "Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 8565. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.8565.

Full text

Abstract:

8565 Background: The BRIGHT study demonstrated that first-line BR was non-inferior to R-CHOP/R-CVP in terms of complete remission rate in indolent NHL and MCL. This is the first detailed analysis of the safety and tolerability of the study regimens. Methods: Patients were preselected for R-CHOP or R-CVP, and then randomized to 6-8 cycles of BR (28-d cycle) or the preselected standard regimen (21-d cycles). BR dosing was bendamustine 90 mg/m2/d as a 30-min infusion on days 1 and 2 plus rituximab 375 mg/m2given before bendamustine on day 1. Colony stimulating factors (CSFs) and antiemetics were given per local standards. Results: In patients preselected for R-CHOP, 103 received BR and 98 R-CHOP. In patients preselected for R-CVP, 118 received BR and 116 R-CVP. For all regimens, ≥ 88% of patients received the planned 6 cycles. Main differences in adverse events (AEs), all grades, are shown in the Table. Incidence of grade 3/4 AEs was 69% for R-CHOP vs 56% BR, and 50% for R-CVP vs 56% BR. Grade 3/4 drug hypersensitivity, neuropathy, and rash were infrequent. Antiemetic use was similar between groups except use of aprepitant as an adjunct to 5-HT3 antagonists was higher with R-CHOP (23% [19% in cycle 1]) than BR (9% [2%]) or R-CVP (3% [2%]). CSF use was higher with R-CHOP (61%) than BR (29%) or R-CVP (27%). Analyses of event prevalence over the treatment period and by region will also be presented. Conclusions: BR, R-CHOP, and R-CVP have significantly distinct AE profiles. More nausea, vomiting, and hypersensitivity occurred with BR while more constipation, neuropathy, and alopecia occurred with RECHOP/R-CVP. Support: Teva BPP R&D, Inc. Clinical trial information: NCT00877006. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

26

D.V., Neizvestnaya. "Application of CVP-Analysis at the Water Transport Organizations." HELIX 8, no. 1 (January 1, 2018): 2811–15. http://dx.doi.org/10.29042/2018-2811-2815.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Yunker, James A., and Dale Schofield. "Pricing training and development programs using stochastic CVP analysis." Managerial and Decision Economics 26, no. 3 (2005): 191–207. http://dx.doi.org/10.1002/mde.1204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Shaw, Dein, Chien Ting Liu, Jyun Yu Cai, and Yuan Cheng Sun. "Efficiency Analysis of Subsystems of Compressed Air Wind Energy System." Applied Mechanics and Materials 284-287 (January 2013): 1039–45. http://dx.doi.org/10.4028/www.scientific.net/amm.284-287.1039.

Full text

Abstract:

This study works on the efficiency analysis of a compressed air wind energy system which is composed of a windmill, a continuous variable planetary (CVP) transmission, a flywheel, a clutch, a reciprocating compressor, and an air tank. To make the system operate at its best performance, the subsystem characteristic must be fully understood. In this study, we examine three main subsystems of the wind energy system: windmill, CVP transmission and reciprocating compressor thoroughly by experiments. The characteristic of these subsystems are discovered based on the different operating conditions. The performance characteristics of these subsystems offer a reference for the operation design of compressed air wind energy system.

APA, Harvard, Vancouver, ISO, and other styles

29

Braga, Paula, Susana Carvalho, Marília Gomes, Lurdes Guerra, Paulo Lúcio, Herlander Marques, Filipa Negreiro, Catarina Pereira, Catarina Silva, and Adriana Teixeira. "Health Outcomes and Costs of Rituximab in Combination with Cyclophosphamide, Vincristine and Prednisolone in the Treatment of Patients with Advanced Follicular Lymphoma in Portugal." Blood 114, no. 22 (November 20, 2009): 2481. http://dx.doi.org/10.1182/blood.v114.22.2481.2481.

Full text

Abstract:

Abstract Abstract 2481 Poster Board II-458 Objective: With the pressure on healthcare budgets, it has become increasingly important for healthcare decision makers to consider the value for money of the treatments they reimburse. The objective of this analysis was to evaluate the long term outcomes and costs of rituximab in combination with cyclophosphamide/vincristine/prednisolone chemotherapy regimen (R-CVP) versus CVP alone, in previously untreated patients with indolent Non-Hodgkin Lymphoma (NHL) from the Portuguese National Health System (NHS) perspective. Methods: Cost-effectiveness (Life Years Gained - LYG) and cost-utility analysis (Quality Adjusted Life years – QALYs) were performed for a time horizon of 10 years, according to a Markov economic model with three health states (“progression free survival”, “progression” and “death”) and monthly cycles for a population of previously untreated patients with indolent NHL. Data from a phase III clinical trial (Marcus 2007) was used and expanded to include unpublished 53-month median follow-up data. Survival after first-line therapy was estimated from the Scotland and Newcastle Lymphoma Group registry data and utilities were derived from a study in the UK performed in patients with follicular lymphoma. Resource consumption was estimated by a Portuguese expert panel (Delbecq Panel). Costs were calculated from the Portuguese NHS perspective through official data with prices updated to 2008. Only direct medical costs were considered. Costs and clinical outcomes were discounted at 5% per annum. Deterministic and probabilistic sensitivity analysis were performed around assumptions on the time horizon, costs, utilities and excess mortality rate due to progression applied in the base-case analysis. Results: The 10-year base-case analysis showed a lower total cost per patient with CVP alone (€ 85,838) in comparison with R-CVP (€ 87,774). Life expectancy and quality-adjusted life expectancy per patient were higher with R-CVP (6.361 and 4.166, respectively) than with CVP alone (5.557 and 3.438, respectively), representing increases of 0.804 in LYG and 0.728 (8.7 months) in QALYs gained. The incremental cost per LYG was € 2,407 and the incremental cost per QALY gained was € 2,661. The probabilistic sensitivity analysis confirmed the robustness of the base-case analysis results. Conclusions: This study demonstrates that the combination R-CVP in previously untreated non-Hodgkin lymphoma patients improves life expectancy and is a cost-effective alternative to CVP in Portugal. Disclosures: Braga: Roche Farmacêutica Química, Lda: Employment. Pereira:Roche Farmacêutica Química, Lda.: Employment.

APA, Harvard, Vancouver, ISO, and other styles

30

Lewis, Gavin, Robert E. Marcus, Stephen J. Proctor, Marlene Gyldmark, James Creeden, Rick Aultman, and Fred Jost. "The Cost-Effectiveness of Rituximab, Cyclophosphamide, Vincristine and Prednisolone (RCVP) Compared with CVP for the Treatment of Follicular Non-Hodgkin’s Lymphoma (NHL) in the UK." Blood 108, no. 11 (November 16, 2006): 345. http://dx.doi.org/10.1182/blood.v108.11.345.345.

Full text

Abstract:

Abstract Background: A large phase III randomised control trial (Marcus et al, Blood2005, 105;4) has demonstrated that rituximab plus CVP compared with CVP alone improved time to treatment failure (p<0.0001) and a trend towards overall survival benefit (p=0.06). No analysis has yet been published relating to long-term clinical outcomes and costs of adding rituximab as a first-line treatment. Cost-effectiveness (CE) analysis aims to evaluate the additional costs and patient benefits (expressed as quality adjusted life years – QALYs) of an intervention (RCVP) compared with an alternative intervention (CVP). Some healthcare systems have CE thresholds to judge if the incremental cost-effectiveness ratio (ICER) is within acceptable limits; these thresholds vary across countries. Aims: To estimate the long-term clinical outcomes, direct health-service costs and incremental CE of RCVP compared with CVP for the first-line treatment of patients with follicular NHL. Methods: A CE analysis was developed using a state-transition Markov model, which simulated the lifetime progression of follicular NHL patients. Baseline patient characteristics were assumed equal to those in the Marcus et al study, with a mean age of 53. The CE of RCVP was evaluated using an ICER, based upon the UK health-service perspective. The model starts from the time of receiving first treatment until death. Patients could be in one of 3 discrete health states: progression-free survival, progression or death. The risk of disease progression for RCVP and CVP patients was derived directly from the results of the Marcus et al study, based upon a median trial follow-up of 42 months. The risk of death following disease progression was based upon outcomes reported by a UK registry of second-line follicular NHL patients (n=249). Patient quality of life was incorporated within the analysis using utility scores for each health state from a survey of follicular NHL patients (n=165) who completed the EQ-5D questionnaire. Cost and QALYs were discounted at 3.5%. Costs for patient monitoring and drug costs for second-line and later treatments were taken from published literature. Second-line and later treatments were assumed equivalent in both arms of the model. Results: Over the lifetime of a patient rituximab as a first-line treatment strategy generated higher total costs, but greater QALYs, compared with CVP alone. The average lifetime health-service costs per patient were £20,347 ($37,650) and £9,977 ($18,462) per patient for RCVP and CVP, respectively. Life expectancy was estimated as 9.4 yrs for RCVP and 7.2 yrs for CVP (undiscounted). Average QALYs for RCVP and CVP were 5.7 and 4.5 per patient, respectively (undiscounted). The ICER (discounted) of RCVP compared with CVP was £8,290 ($15,340) per QALY. Although there is uncertainty associated with the progression of follicular lymphoma and treatment costs, the ICER did not exceed £21,500 ($39,784) despite a wide variation in each parameter used in the analysis. Conclusions: Rituximab in combination with CVP is a cost-effective treatment option for the first-line treatment of follicular NHL. The clinical advantages of RCVP compared with CVP alone are predicted to generate an increase in life expectancy and QALYs. The resulting ICER for RCVP is well within the UK threshold of CE.

APA, Harvard, Vancouver, ISO, and other styles

31

Marcus, Robert E., Philippe Solal-Celigny, Kevin Imrie, John V. Catalano, Anna Dmoszynska, João C. Raposo, Fritz C. Offner, and José Gomez-Codina. "MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL)." Blood 108, no. 11 (November 16, 2006): 481. http://dx.doi.org/10.1182/blood.v108.11.481.481.

Full text

Abstract:

Abstract Design/methods: Rituximab added to 8 cycles of CVP (R-CVP) chemotherapy improves time to progression and duration of response in previously untreated patients with stage III/IV CD20 positive follicular NHL compared with CVP alone (Marcus et al Blood2005;105:1417–23). A protocol pre-planned analysis of this study with a median follow-up of 53 months has now been performed. Results: A total of 321 patients (median age 53 years) were recruited. Eighty-three percent of patients in both arms had intermediate to high-risk disease according to the Follicular Lymphoma International Prognostic Index (FLIPI, score 2–5). Median time to progression or death (TTP) in the R-CVP arm was 34 months compared with 15 months in the CVP arm, p<0.0001 (log rank). This increase in TTP was observed in all FLIPI groups with a risk ratio of 0.40 (95% confidence interval 0.27 to 0.60) for good intermediate risk patients and 0.51 (95% confidence interval 0.34 to 0.76) for poor risk patients; overall the risk ratio was 0.44 (95% confidence interval 0.32 to 0.57). In patients achieving a complete response (CR) or CR unconfirmed (CRu), disease-free survival (DFS) was significantly prolonged (p=0.0001, log rank); the estimated 4-years’ DFS rate was 54% for patients receiving R-CVP compared with 17% for CVP. Nineteen percent (31/162) of patients in the R-CVP group have now died compared with 29% (46/159 patients) in the CVP group. Patients receiving R-CVP had a significant improvement in overall survival compared with CVP (p=0.03, log rank; hazard ratio 0.60 [95% confidence interval 0.38 to 0.96]). Conclusion: When added to first-line chemotherapy in patients with follicular NHL, rituximab not only improves TTP and DFS, but also has a favorable effect on overall survival.

APA, Harvard, Vancouver, ISO, and other styles

32

Bagheri, Rasool, Ismail Ebrahimi Takamjani, Mohammad R. Pourahmadi, Elham Jannati, Sayyed H. Fazeli, Rozita Hedayati, and Mahmood Akbari. "Trunk–Pelvis Kinematics Variability During Gait and Its Association With Trunk Muscle Endurance in Patients With Chronic Low Back Pain." Journal of Applied Biomechanics 36, no. 2 (April 1, 2020): 76–84. http://dx.doi.org/10.1123/jab.2019-0322.

Full text

Abstract:

The first purpose was to investigate the trunk muscle endurance, the second aim was to evaluate the trunk–pelvis kinematics during gait, and the third was to evaluate the relationship between trunk–pelvis kinematics and the trunk muscle endurance. Thirty participants (15 nonspecific chronic low back pain [NCLBP] and 15 healthy) were included. The authors first assessed trunk muscle endurance on endurance testing protocols. The authors next measured the trunk–pelvis kinematics during gait using a 3-dimensional motion capture system. Angular displacement, waveform pattern (CVp), and offset variability (CVo) were also examined. Statistical analysis revealed a significant difference in (1) the trunk muscle endurance and (2) sagittal, frontal, and transverse planes CVp between groups (P < .05). A significant moderate correlation was found between supine double straight-leg raise and frontal CVp (r = .521, P = .03) and transverse planes CVp (r = .442, P = .05). However, a significant moderate correlation was observed between prone double straight-leg raise and sagittal plane CVp (r = .528, P = .03) and transverse plane CVp (r = .678, P = .001). The relationship between (1) lower trunk extensor endurance with transverse and sagittal planes CVp and (2) lower abdominal muscle endurance with transverse and frontal planes CVp suggests that gait variability in these planes may result because of trunk muscle deconditioning accompanying NCLBP.

APA, Harvard, Vancouver, ISO, and other styles

33

Hornberger, J., C. Reyes, E. Verhulst, D. Lubeck, and N. Valente. "Cost-effectiveness of rituximab plus CVP for first-line treatment of advanced indolent lymphoma." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 6583. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.6583.

Full text

Abstract:

6583 Background: The addition of rituximab (RTX) to CVP (cyclophosphamide, vincristine, prednisone) in the treatment of advanced follicular lymphoma increases median time to progression by 17 months (15 month v 32 months; p < 0.0001) (Marcus et al, Blood 2005). A societal cost-effectiveness analysis was performed to estimate projected lifetime clinical and economic implications of this treatment. Methods: The cost-effectiveness (CE) of RTX + CVP versus CVP was estimated for a 50 yr old patient. Kaplan-Meier estimates of progression-free and overall survival, up to 4 years, were obtained from the M39021 trial. After 4 years, transition rates from initiation of treatment to progression or death were assumed to be the same in both arms. The clinical and economic implications of relapse and its treatment were included in the model. Incremental costs associated with addition of RTX were estimated using Medicare reimbursement rates and published retail price data. Costs included drug and administration costs, adverse events, treatment of relapses, and end-of-life costs. Utility estimates were derived from the literature and a 3% discount rate was employed. Results: Projected mean overall survival is 1.5 yrs longer for patients assigned to RTX+ CVP versus only CVP (13.7 v 12.2 yrs). The addition of RTX to CVP is estimated to cost an additional $26,439 on average, with an expected gain of 0.85 year of quality-adjusted survival. Over a lifetime, the cost per QALY gained is $31,329. Sensitivity analyses revealed that the variables that most influenced cost-effectiveness were the time horizon (range: $18,800- $31,240) and the unit drug cost of RTX (range: $24,000-$38,000). Conclusion: The model estimates a cost-to-QALY gained ratio that is below that of many treatments used for oncology patients. The use of RTX + CVP for first-line treatment of advanced follicular lymphoma is projected to be cost-effective compared to CVP alone under a range of sensitivity analyses. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

34

Zhao, Lihui, and Zihui Yang. "Time-Driven Activity-Based Cost Expansion Model." Journal of Engineering, Project, and Production Management 12, no. 2 (May 1, 2022): 116–25. http://dx.doi.org/10.32738/jeppm-2022-0011.

Full text

Abstract:

The classic Cost-Volume-Profit (CVP) model cannot meet the needs of accurate decision-making under the new cost structure, and the time-driven activity-based costing can accurately and timely respond to rising overhead costs through accurate identification of time-related resource consumption. By relaxing the constraints of the CVP model, based on the time-driven activity-based costing method, this paper reclassifies and divides the cost behavior, constructs an extended CVP analysis model, and uses the operating data of Hunan Gongsheng Fengsheng Equipment Manufacturing Co., Ltd (GSFS) to conduct the empirical analysis. The results show that the extended model is reliable and effective.

APA, Harvard, Vancouver, ISO, and other styles

35

Stępień, Beata. "In Search of Apprehending Customers’ Value Perception." International Journal of Management and Economics 53, no. 1 (March 1, 2017): 99–117. http://dx.doi.org/10.1515/ijme-2017-0007.

Full text

Abstract:

AbstractThe article clarifies the concept of value for customer, demonstrates challenges related to the concept itself and its measurement and sheds new light on the consequences of conceptual and metric choices. The analysis focuses on three points: first, it shows, how the definition and delineation of customer perceived value (CVP) implies the choice of certain measurement tools, but does not necessarily reveal the essence of the measured construct. Second, it provides a quantitative measure of CVP components showing the functional interconnections between them without presenting their causal relations. Third, it suggests the priority of a theoretical conceptualization over any technical craft considerations in CVP measurement.The article begins with mapping and deconstructing the value concept, which is followed by a critical discussion of its measurement challenges. Mixed methodology for empirical exploration of CVP construct is recommended here, being as the approach that blends quantitative methods with a deeper understanding of CVP provided by qualitative tools.

APA, Harvard, Vancouver, ISO, and other styles

36

Karpavičiūtė, Justina, Inga Skarupskienė, Vilma Balčiuvienė, Rūta Vaičiūnienė, Edita Žiginskienė, and Inga Arūnė Bumblytė. "Assessment of Fluid Status by Bioimpedance Analysis and Central Venous Pressure Measurement and Their Association with the Outcomes of Severe Acute Kidney Injury." Medicina 57, no. 6 (May 22, 2021): 518. http://dx.doi.org/10.3390/medicina57060518.

Full text

Abstract:

Background and Objectives: Fluid disbalance is associated with adverse outcomes in critically ill patients with acute kidney injury (AKI). In this study, we intended to assess fluid status using bioimpedance analysis (BIA) and central venous pressure (CVP) measurement and to evaluate the association between hyperhydration and hypervolemia with the outcomes of severe AKI. Materials and Methods: A prospective study was conducted in the Hospital of the Lithuanian University of Health Sciences Kauno Klinikos. Forty-seven patients treated at the Intensive Care Unit (ICU) with severe AKI and a need for renal replacement therapy (RRT) were examined. The hydration level was evaluated according to the ratio of extracellular water to total body water (ECW/TBW) of bioimpedance analysis and volemia was measured according to CVP. All of the patients were tested before the first hemodialysis (HD) procedure. Hyperhydration was defined as ECW/TBW > 0.39 and hypervolemia as CVP > 12 cm H2O. Results: According to bioimpedance analysis, 72.3% (n = 34) of patients were hyperhydrated. According to CVP, only 51.1% (n = 24) of the patients were hypervolemic. Interestingly, 69.6% of hypovolemic/normovolemic patients were also hyperhydrated. Of all study patients, 57.4% (n = 27) died, in 29.8% (n = 14) the kidney function improved, and in 12.8% (n = 6) the demand for RRT remained after in-patient treatment. A tendency of higher mortality in hyperhydrated patients was observed, but no association between hypervolemia and outcomes of severe AKI was established. Conclusions: Three-fourths of the patients with severe AKI were hyperhydrated based on bioimpedance analysis. However, according to CVP, only half of these patients were hypervolemic. A tendency of higher mortality in hyperhydrated patients was observed.

APA, Harvard, Vancouver, ISO, and other styles

37

Sehn, Laurie H., David MacDonald, Sheldon Rubin, Guy Cantin, Morel Rubinger, Bernard Lemieux, Sanraj Basi, et al. "Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group." Journal of Clinical Oncology 29, no. 25 (September 1, 2011): 3396–401. http://dx.doi.org/10.1200/jco.2010.33.6594.

Full text

Abstract:

Purpose Bortezomib has demonstrated promising activity in patients with follicular lymphoma (FL). This is the first study to evaluate the safety and efficacy of bortezomib added to rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) in previously untreated advanced-stage FL. Patients and Methods This is a phase II multicenter trial adding bortezomib (1.3 mg/m2 days 1 and 8) to standard-dose R-CVP (BR-CVP) for up to eight cycles in patients with newly diagnosed stage III/IV FL requiring therapy. Two co-primary end points, complete response rate (complete response [CR]/CR unconfirmed [CRu]) and incidence of grade 3 or 4 neurotoxicity, were assessed. Results Between December 2006 and March 2009, 94 patients were treated with BR-CVP. Median patient age was 57 years (range, 29 to 84 years), and the majority had a high (47%) or intermediate (43%) Follicular Lymphoma International Prognostic Index score. BR-CVP was extremely well tolerated, with 90% of patients completing the intended eight cycles. No patients developed grade 4 neurotoxicity, and only five of 94 patients (5%; 95% CI, 0.8% to 9.9%) developed grade 3 neurotoxicity, which was largely reversible. On the basis of an intention-to-treat analysis, 46 of 94 patients (49%; 95% CI, 38.8% to 59.0%) achieved a CR/CRu, and 32 of 94 patients (34%) achieved a partial response, for an overall response rate of 83% (95% CI, 75.4% to 90.6%). Conclusion The addition of bortezomib to standard-dose R-CVP for advanced-stage FL is feasible and well tolerated with minimal additional toxicity. The complete response rate in this high-risk population compares favorably to historical results of patients receiving R-CVP. Given these results, a phase III trial comparing BR-CVP with R-CVP is planned.

APA, Harvard, Vancouver, ISO, and other styles

38

DOGADAYLO, Ya, and A. LABOONSKAYA. "THE ESSENCE AND PURPOSE OF CVP-ANALYSIS IN MODERN CONDITIONS." Economics of the transport complex, no. 33 (May 14, 2019): 70. http://dx.doi.org/10.30977/etk.2225-2304.2019.33.0.70.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Tsai, Wen-Hsien, and Tsong-Ming Lin. "Nonlinear multiproduct CVP analysis with 0–1 mixed integer programming." Engineering Costs and Production Economics 20, no. 1 (July 1990): 81–91. http://dx.doi.org/10.1016/0167-188x(90)90012-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Atefvahid, Parham, Kamran Hassani, Kamal Jafarian, D. John Doyle, and Hessam Ahmadi. "Analysis of central venous pressure (CVP) signals using mathematical methods." Journal of Clinical Monitoring and Computing 31, no. 3 (May 3, 2016): 607–16. http://dx.doi.org/10.1007/s10877-016-9882-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Flinn, Ian, Richard van der Jagt, Julie E. Chang, Peter Wood, Tim E. Hawkins, David MacDonald, Judith Trotman, et al. "First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 7500. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7500.

Full text

Abstract:

7500 Background: BRIGHT, a phase 3, open-label, noninferiority study comparing efficacy and safety of bendamustine plus rituximab (BR) vs rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or rituximab with cyclophosphamide, vincristine and prednisone (R-CVP) in treatment-naive patients (pts) with indolent non-Hodgkin lymphoma (iNHL) or mantle cell lymphoma (MCL), showed that the complete response rate for first-line BR was statistically noninferior to R-CHOP/R-CVP ( Blood 2014). Pts were monitored for ≥5 years (yr) to assess the overall effect of BR or R-CHOP/R-CVP in a controlled clinical setting. This analysis reports the time-to-event variables of the 5-yr follow-up (FU) study. Methods: Pts with iNHL or MCL randomized to 6-8 cycles of BR or R-CHOP/R-CVP underwent complete assessments at end of treatment, then were monitored regularly. Progression-free survival (PFS), event-free survival (EFS), duration of response (DOR) and overall survival (OS) were compared using a stratified log-rank test. Results: Of 447 randomized pts, 224 received BR, 104 R-CHOP, and 119 R-CVP; 419 entered the FU. The median FU time was 65.0 and 64.1 months for BR and R-CHOP/R-CVP, respectively. The 5-yr PFS rate was 65.5% (95% CI 58.5-71.6) and 55.8% (48.4-62.5), and OS was 81.7% (75.7-86.3) and 85% (79.3-89.3) for BR and R-CHOP/R-CVP, respectively. The hazard ratio (95% CI) for PFS was 0.61 (0.45-0.85; P= .0025), EFS 0.63 (0.46-0.84; P= .0020), DOR 0.66 (0.47-0.92; P= .0134), and OS 1.15 (0.72-1.84; P= .5461) comparing BR vs R-CHOP/R-CVP. Similar results were found in iNHL [PFS 0.70 (0.49-1.01; P= .0582)] and MCL [PFS 0.40 (0.21-0.75; P= .0035)], with the strongest effect in MCL. Use of R maintenance was similar, 43% in BR and 45% in R-CHOP/R-CVP. B was included as second-line in 27 (36%) of the 75 pts requiring therapy who originally received R-CHOP/R-CVP. Comparable safety profiles with expected adverse events were observed in the FU study in BR vs R-CHOP/R-CVP. Conclusions: The long-term FU of the BRIGHT study has confirmed that PFS, EFS, and DOR were significantly better for BR, and OS was not statistically different between BR and R-CHOP/R-CVP. The safety profile was as previously reported. Clinical trial information: NCT00877006.

APA, Harvard, Vancouver, ISO, and other styles

42

Raymundo, H., A. M. Scher, D. S. O'Leary, and P. D. Sampson. "Cardiovascular control by arterial and cardiopulmonary baroreceptors in awake dogs with atrioventricular block." American Journal of Physiology-Heart and Circulatory Physiology 257, no. 6 (December 1, 1989): H2048—H2058. http://dx.doi.org/10.1152/ajpheart.1989.257.6.h2048.

Full text

Abstract:

We studied reflex responses to pressure changes at arterial and cardiopulmonary baroreceptors in five awake dogs with atrioventricular block before and after baroreceptor denervation. We changed ventricular pacing rate and blood volume to vary cardiac output and arterial (MAP) and central venous pressure (CVP). We determined peripheral resistance (TPR) and atrial rate (HRA) as responses. In the intact animal, regression analysis showed an average relationship across dogs of TPR = 169-0.69 MAP-1.952 CVP + error. Correlation (r) between observed and predicted TPR was 0.83. For HRA, regression indicated HRA = 291.66-2.319 MAP + 8.144 CVP + error (r = 0.899). TPR and MAP are percent of control at 90 beats/min; CVP is in mmHg; HRA, in beats/min. Although its coefficient is smaller, MAP explains approximately 69% of the variation in TPR. After arterial baroreceptor denervation, effects of MAP on TPR were insignificant and the coefficient for CVP increased. Subsequent vagal block eliminated all reflex responses. Effects from the two receptor sites sum linearly. They act cooperatively with changes in blood volume, but oppose one another with cardiac output changes.

APA, Harvard, Vancouver, ISO, and other styles

43

Barbieri, Riccardo, John K. Triedman, and J. Philip Saul. "Heart rate control and mechanical cardiopulmonary coupling to assess central volume: a systems analysis." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 283, no. 5 (November 1, 2002): R1210—R1220. http://dx.doi.org/10.1152/ajpregu.00127.2002.

Full text

Abstract:

Small negative changes of central volume reduce cardiac output without significant alterations of arterial blood pressure (ABP), suggesting an adequate regulatory response. Furthermore, evidence has arisen supporting a Bainbridge reflex (tachycardia with hypervolemia) in humans. To investigate these phenomena, multivariate autoregressive techniques were used to evaluate the beat-to-beat interactions between respiration, R-R interval, and ABP at six levels of decreased and increased central volume. With reductions of central volume below control, baroreflex and respiratory sinus arrhythmia gains were reduced, while with increases of volume above control, gains increased for the first two levels but decreased again at the highest volume level, suggesting the presence of a Bainbridge reflex in healthy human subjects. The mechanical influence of respiration on central venous pressure (CVP) had an unexpected shift in phase at the point of mild central hypervolemia, with the expected negative relation at lower volumes (inspiration lowers CVP) but a positive relation at higher volumes (inspiration raises CVP). We conclude that multivariate techniques can quantify the relations between a variety of respiratory and hemodynamic parameters, allowing for the in vivo assessment of complex cardiorespiratory interactions during manipulations of central volume. The results identify the presence of a Bainbridge reflex in humans and suggest that short-term cardiovascular control is optimized at mild hypervolemia.

APA, Harvard, Vancouver, ISO, and other styles

44

Seo, S. Niggol. "Decision Making under Climate Risks: An Analysis of Sub-Saharan Farmers’ Adaptation Behaviors." Weather, Climate, and Society 4, no. 4 (October 1, 2012): 285–99. http://dx.doi.org/10.1175/wcas-d-12-00024.1.

Full text

Abstract:

Abstract This paper examines decision making under climate risks using farmers’ decisions in sub-Saharan Africa, where climate risks are very high. Two risk measures are obtained from the Climate Research Unit’s high-resolution climatology, diurnal temperature range (DTR) and coefficient of variation in precipitation (CVP), which are both averages of 30-yr climate data. Farm surveys of around 7600 households were matched cell by cell with the climate risk data. This paper finds that climate risks are indeed highest in the lowland arid zones in the Sahel. A spatial logit analysis shows that farmers in sub-Saharan Africa have adapted their agricultural systems to varying degrees of the CVP and the DTR. In the long term, if the CVP were to increase by 30%, an integrated system would increase by 7.0%. On the other hand, the two specialized systems fall: a crops-only system falls by 5.3% and a livestock-only system falls by 1.7%. When the DTR increases, farmers adapt by switching to a specialized livestock system. Under increased climate risks, this paper finds that farmers in the lowland savannahs and arid zones in the Sahel, where climate risks are high at present, will adapt by switching to an integrated system. Studies of climate risks, therefore, must account for behavioral responses of the individuals. These results can be utilized to help African farmers to adapt to increasing climate risks.

APA, Harvard, Vancouver, ISO, and other styles

45

Johnson, Blair D., Noud van Helmond, Timothy B. Curry, Camille M. van Buskirk, Victor A. Convertino, and Michael J. Joyner. "Reductions in central venous pressure by lower body negative pressure or blood loss elicit similar hemodynamic responses." Journal of Applied Physiology 117, no. 2 (July 15, 2014): 131–41. http://dx.doi.org/10.1152/japplphysiol.00070.2014.

Full text

Abstract:

The purpose of this study was to compare hemodynamic and blood analyte responses to reduced central venous pressure (CVP) and pulse pressure (PP) elicited during graded lower body negative pressure (LBNP) to those observed during graded blood loss (BL) in conscious humans. We hypothesized that the stimulus-response relationships of CVP and PP to hemodynamic responses during LBNP would mimic those observed during BL. We assessed CVP, PP, heart rate, mean arterial pressure (MAP), and other hemodynamic markers in 12 men during LBNP and BL. Blood samples were obtained for analysis of catecholamines, hematocrit, hemoglobin, arginine vasopressin, and blood gases. LBNP consisted of 5-min stages at 0, 15, 30, and 45 mmHg of suction. BL consisted of 5 min at baseline and following three stages of 333 ml of hemorrhage (1,000 ml total). Individual r2 values and linear regression slopes were calculated to determine whether the stimulus (CVP and PP)-hemodynamic response trajectories were similar between protocols. The CVP-MAP trajectory was the only CVP-response slope that was statistically different during LBNP compared with BL (0.93 ± 0.27 vs. 0.13 ± 0.26; P = 0.037). The PP-heart rate trajectory was the only PP-response slope that was statistically different during LBNP compared with BL (−1.85 ± 0.45 vs. −0.46 ± 0.27; P = 0.024). Norepinephrine, hematocrit, and hemoglobin were all lower at termination in the BL protocol compared with LBNP ( P < 0.05). Consistent with our hypothesis, LBNP mimics the hemodynamic stimulus-response trajectories observed during BL across a significant range of CVP in humans.

APA, Harvard, Vancouver, ISO, and other styles

46

Andi, Muliati, and Rahim Syamsuri. "INTEGRATION OF COST VOLUME PROFIT AND ACTIVITY BASED COSTING IN OBTAINING COST ACCURACY FOR DECISION MAKING." Jurnal RAK (Riset Akuntansi Keuangan) 5, no. 2 (October 30, 2020): 109–18. http://dx.doi.org/10.31002/rak.v5i2.3657.

Full text

Abstract:

his study aims to provide an explanation of how the integration of CVP and ABC can provide results of analysis and information that is more accurate than the traditional CVP on Elegant Photography to be used as a basis for decision making. The method used in this research is descriptive quantitative method by collecting data and information from the research location directly through interviews, observation and documentation. Furthermore, data and information analysis is obtained using cost volume profit analysis tools including break-even analysis, profit planning, margin of safety, shut down point, degree of operating leverage, and contribution margin and Activity based costing. The results obtained from this study provide the availability of more accurate and varied information. The CVP analysis results show the number of break-even points, earnings plans and contribution margins. As well as showing excellent performance in terms of the percentage of MOS and DOL while ABC analysis provides information about better cost accuracy so that the data and information from these two Terk can be the basis for strategic decision making for management

APA, Harvard, Vancouver, ISO, and other styles

47

Anish Kafoor, N., M. Vijayakumar, A. Ramesh, and P. Selvakumar. "Cryogenic viscous pump analysis based on hemisphere model." Journal of Physics: Conference Series 2054, no. 1 (October 1, 2021): 012068. http://dx.doi.org/10.1088/1742-6596/2054/1/012068.

Full text

Abstract:

Abstract Cryogenic viscous pump (CVP) is also known as fore pump that are mainly designed for the separation of hydrogen isotopes from the helium during the process of regeneration of cryo- pumps. This model will determine the amount of hydrogen which is extracted by supercritical helium cooled pump. It also includes flow rates and inlet conditions that are related to the hydrogen gas flow. This hemisphere model (HM) determines the amount and location which are extracted by the pump as the function of time. During the development of this model the calibration check done for its results, later it has been compared with the measurements of CFP prototype. At the result of this model, it will demonstrate the quantity of hydrogen which is very sensitive to the inlet temperature that is found outside of the Cryopump. Finally, this model will represent the efficient outcome.

APA, Harvard, Vancouver, ISO, and other styles

48

Dundar, Y., A. Bagust, J. Hounsome, C. McLeod, A. Boland, H. Davis, T. Walley, and R. Dickson. "Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma." Health Technology Assessment 13, Suppl 1 (June 2009): 23–28. http://dx.doi.org/10.3310/hta13suppl1-04.

Full text

Abstract:

This paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma (FNHL) based upon the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The manufacturer’s scope restricts the intervention to rituximab in combination with CVP (cyclophosphamide, vincristine and prednisolone) (R-CVP); the only comparator used was CVP alone. The evidence from the one included randomised controlled trial (RCT) suggests that the addition of rituximab to a CVP chemotherapy regimen has a positive effect on the outcomes of time to treatment failure, disease progression, overall tumour response, duration of response and time to new lymphoma treatment in patients with stage III/IV FNHL compared with CVP alone. Adverse events were comparable between the two arms. This study was confirmed as the only relevant RCT. The economic analyses provided by the manufacturer were modelled using a three-state Markov model with with the health states being defined as progression-free survival (PFS), progressed (in which patients have relapsed) and death (which is an absorbing state). The model generated results for a cohort of patients with an initial age of 53 and makes no distinction between men and women. The model is basic in design, with several serious design flaws and key parameter values that are probably incompatible. Attempting to rectify the identified errors and limitations of the model did not increase the incremental cost-effectiveness ratio (ICER) above £30,000. Although the cost-effectiveness results obtained appear to be compelling in support of R-CVP compared with CVP for the trial population the results may not be so convincing for a more representative population. The results of the ERG analysis on the impact of age suggest that ICERs increase steadily with age, as the proportion of PFS that can be converted to overall survival (OS) is diminished by rising mortality rates in the general population. For the most extreme scenario (no OS gain) the ICER appears to remain below £30,000 per QALY gained. On balance the evidence indicates that R-CVP is more cost-effective than CVP. The guidance issued by NICE in July 2006 as a result of the STA states that rituximab within its licensed indication (in combination with cyclophosphamide, vincristine and prednisolone) is recommended as an option for the treatment of symptomatic stage III/IV follicular non-Hodgkin’s lymphoma in previously untreated patients.

APA, Harvard, Vancouver, ISO, and other styles

49

LAU, AMY HING-LING, and HON-SHIANG LAU. "CVP analysis with stochastic price-demand functions and shortage-surplus costs." Contemporary Accounting Research 4, no. 1 (September 1987): 194–209. http://dx.doi.org/10.1111/j.1911-3846.1987.tb00663.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Yunker, James A., and Penelope J. Yunker. "Stochastic CVP analysis as a gateway to decision-making under uncertainty." Journal of Accounting Education 21, no. 4 (October 2003): 339–65. http://dx.doi.org/10.1016/j.jaccedu.2003.09.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'CVP analysis'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles